Jacobs Levy Equity Management, Inc Macrogenics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 566,328 shares of MGNX stock, worth $2.16 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
566,328
Previous 418,890
35.2%
Holding current value
$2.16 Million
Previous $1.78 Million
4.66%
% of portfolio
0.01%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding MGNX
# of Institutions
133Shares Held
55.4MCall Options Held
199KPut Options Held
99.2K-
Bellevue Group Ag Kuesnacht, V89.93MShares$37.8 Million0.55% of portfolio
-
Armistice Capital, LLC New York, NY6.26MShares$23.8 Million0.34% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$20.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$16.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.54MShares$13.5 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $234M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...